Inventiva (NASDAQ:IVA – Get Free Report) is expected to be posting its Q2 2026 results after the market closes on Friday, September 25th. Analysts expect Inventiva to post earnings of ($0.20) per share and revenue of $6.3470 million for the quarter. Parties can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, September 28, 2026 at 8:00 AM ET.
Inventiva Price Performance
Shares of IVA opened at $3.65 on Wednesday. Inventiva has a 52-week low of $3.35 and a 52-week high of $7.98. The stock has a fifty day simple moving average of $4.49 and a two-hundred day simple moving average of $4.81.
Analyst Ratings Changes
A number of equities analysts have commented on the stock. Cantor Fitzgerald assumed coverage on shares of Inventiva in a research note on Friday, July 17th. They set an “overweight” rating on the stock. Piper Sandler reissued an “overweight” rating on shares of Inventiva in a research note on Wednesday, September 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Inventiva in a report on Friday, July 17th. Finally, Guggenheim lifted their price target on shares of Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Three analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $15.75.
About Inventiva
Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.
Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.
Featured Articles
- Five stocks we like better than Inventiva
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Inventiva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inventiva and related companies with MarketBeat.com's FREE daily email newsletter.
